Initially described by Johnson and colleagues in 1987 as a tumor antigen expressed on advanced primary melanoma and metastatic lesions, CD146 was later found to be overexpressed in a broad range of cancer cell lines not limited to pancreatic, breast, prostate, ovarian, lung, kidney cancers, osteosarcoma, Kaposi sarcoma, angiosarcoma, glioblastoma, and leiomyosarcoma [14,20,24]. This evidence concerns the gene MCAM and osteosarcoma.